Author at Microdose

James Hallifax

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Finance

8 May 2023

Which Psychedelic Medicine Companies Have the Best Financials?

As I have written many times before, the success or failure of a psychedelic medicine company depends heavily on its financial position....

By James Hallifax

Industry

18 Apr 2023

LSD Decreased Depression Symptoms by 50% in New MindMed Study

On April 14th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO: MMED) released preliminary data from a Phase 2 clinical trial, which attempted to treat Major Depressive Disorder (MDD) with LSD-assisted...

By James Hallifax

Industry

5 Apr 2023

Small Pharma Announces Positive 6-month Data from Phase 2a DMT Trial

Small Pharma releases additional data from its Phase 2 trial — nearly 2/3 of patients remained in remission after 6 months....

By James Hallifax

Finance

3 Apr 2023

Chrisitian Angermayer Shows Faith in Atai, Buys Another 1.2 M Shares

On March 29th, Christian Angermayer, Founder and Chairman of atai Life Sciences (Nasdaq: ATAI), announced that he was buying more shares of the psychedelic medicines and biotechnology company....

By James Hallifax

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

9 Mar 2023

Are LSD and r-MDMA the Future of Psychedelics? MindMed Says Yes

On March 8th, MindMed CEO Robert Barrow spoke for 30 minutes at the 43rd annual Cowen Healthcare Conference....

By James Hallifax

Industry

6 Mar 2023

The Importance of Cybin’s Next-Generation Psilocybin

Cybin presented data from its ongoing next-generation psilocybin clinical trial during the company’s R&D day....

By James Hallifax

Industry

23 Feb 2023

Compass Pathways’ New Psilocybin For Depression Trial, Explained

On February 17th, psychedelic medicine company Compass Pathways (Nasdaq: CMPS) registered a new Phase 2 clinical trial attempting to treat Major Depressive Disorder using psilocybin-assisted therapy....

By James Hallifax

Law & Politics

9 Feb 2023

Australia Legalizes Psychedelics: Are the US and Canada Next?

Australia has legalized psychedelic therapy, could either Canada or the USA be next to legalize medical psilocybin and MDMA?...

By James Hallifax

Law & Politics

8 Feb 2023

In Defence of Psychedelic Capitalism

While it may be correct to be concerned about psychedelic capitalism - there's no denying that there are some benefits as well....

By James Hallifax

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads